LONN.SW
$488.30
Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally.
Recent News
45% earnings growth over 1 year has not materialized into gains for Lonza Group (VTX:LONN) shareholders over that period
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. Active...
Lonza Group AG's (VTX:LONN) Intrinsic Value Is Potentially 26% Below Its Share Price
Key Insights Lonza Group's estimated fair value is CHF412 based on 2 Stage Free Cash Flow to Equity Lonza Group is...
Can Mixed Fundamentals Have A Negative Impact on Lonza Group AG (VTX:LONN) Current Share Price Momentum?
Most readers would already be aware that Lonza Group's (VTX:LONN) stock increased significantly by 8.8% over the past...
Lonza confirms "long-term commercial supply agreement" at U.S. biologic drug site
Investing.com - Shares of Lonza spiked in early European trading on Thursday after the Swiss contract pharmaceutical firm confirmed a "significant" long-term commercial supply agreement at one of the world’s largest manufacturing sites for biologic drugs in the United States.
Is Now An Opportune Moment To Examine Lonza Group AG (VTX:LONN)?
Lonza Group AG ( VTX:LONN ) saw significant share price movement during recent months on the SWX, rising to highs of...